Salter Malcolm 4
4 · C4 Therapeutics, Inc. · Filed Oct 6, 2020
Insider Transaction Report
Form 4
Salter Malcolm
Director
Transactions
- Conversion
Common Stock
2020-10-06+11,856→ 11,856 total - Conversion
Common Stock
2020-10-06+2,823→ 14,679 total - Purchase
Common Stock
2020-10-06$19.00/sh+1,315$24,985→ 15,994 total - Conversion
Series A Preferred Stock
2020-10-06−100,000→ 0 total→ Common Stock (11,856 underlying) - Conversion
Series B Preferred Stock
2020-10-06−23,809→ 0 total→ Common Stock (2,823 underlying)
Footnotes (1)
- [F1]Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.